BioProcess Insider - News BioProcess International

Thermo Fisher: ‘$700m COVID CapEx easily repurposed post-pandemic’

An additional $700 million capacity buildout to meet COVID-related demand will serve the longer-term non-pandemic-related biopharma market, says Thermo Fisher An unprecedented third quarter saw Thermo Fisher report a 36% rise in revenues year-on-year to $8.52 billion across all its segments. Its ...

Pall and Cytiva reaping $1bn coronavirus bonus for Danaher
Danaher Corporation says its bioprocessing businesses Pall Biotech and Cytiva have secured over $1 billion in COVID-19 related orders and expects ...
Sartorius revises 2020 forecast on bioprocess solutions and lab services growth
Sartorius has raised its guidance citing growing demand for bioprocessing tech and lab services and the positive impact of acquisitions. Group ...
EMA committee nod for Orchard’s Libmeldy positive for AGC Biologics
AGC Biologics looks set to start making Orchard Therapeutics’ Libmeldy after an EMA panel recommended the gene therapy be approved. The agen ...
Swiss plant demonstrates synergies of KBI and Selexis acquisitions for JSR
A facility in Geneva will be home to two of JSR Life Sciences acquisitions offering customers both cell line development and drug substance manuf ...

Covering the whole development process for the global biotechnology industry

More From BioProcess Insider

Recent Tweets

Recent Tweets

Trending